@ultkiof's K-pop video has nothing to do with GLP-1 drugs
Quick answer
GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking hormones that regulate blood sugar and slow gastric emptying, leading to reduced appetite. The STEP 1 trial demonstrated 14.9% body weight loss with 2.4mg weekly semaglutide over 68 weeks.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this video actually claim about GLP-1 drugs?
This TikTok makes zero claims about semaglutide, tirzepatide, or any weight management medications. It's a K-pop fan video featuring the song "Kiss of Life" with dance moves and music.
The video was incorrectly categorized as GLP-1 content, likely due to an algorithmic error or content management system mistake. @ultkiof posted standard K-pop fan content with hashtags like #kissoflife, #kiof, and #kpop.
There's literally nothing here to fact-check regarding Ozempic, Wegovy, Mounjaro, or Zepbound. The 196.1K views came from K-pop fans, not people seeking medical information.
How did this get categorized as medical content?
Content management systems sometimes misclassify videos when automated tagging goes wrong. Social media platforms use AI to categorize millions of posts daily, and errors happen.
This appears to be a straightforward case of mistaken identity. The creator posted entertainment content that somehow got flagged as pharmaceutical discussion.
It's a reminder that not everything labeled as "health content" actually contains health information. Always check what you're actually watching before trusting medical categorization.
What should you know about actual GLP-1 content on social media?
Real GLP-1 videos typically discuss weight loss experiences, side effects, or injection techniques. The STEP 1 trial (Wilding et al., NEJM, 2021) showed 14.9% weight loss with 2.4mg semaglutide at 68 weeks.
Legitimate creators often share specific dosing information, like starting at 0.25mg weekly or reaching 2.4mg maintenance doses. They discuss real side effects like nausea, which affected 44% of participants in clinical trials.
If you're looking for actual GLP-1 information, seek out creators who cite studies and discuss real medical experiences, not dance videos that got miscategorized.
Why does this categorization error matter?
Misclassified content can confuse people genuinely seeking medical information. When entertainment gets tagged as health advice, it dilutes the pool of useful resources.
People researching semaglutide or tirzepatide need accurate information, not K-pop videos. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found 20.9% weight loss with 15mg tirzepatide, but you won't learn that from dance content.
Always verify that health-tagged content actually contains health information before considering any medical decisions.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @ultkiof's K-pop video has nothing to do with GLP-1 drugs, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@ultkiof's K-pop video has nothing to do with GLP-1 drugs should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking hormones that regulate blood sugar and slow gastric emptying, leading to reduced appetite.
FormBlends verdict
GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking hormones that regulate blood sugar and slow gastric emptying, leading to reduced appetite. The STEP 1 trial demonstrated 14.9% body weight loss with 2.4mg weekly semaglutide over 68 weeks.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide and tirzepatide work by mimicking hormones that regulate blood sugar and slow gastric emptying, leading to reduced appetite. The STEP 1 trial demonstrated 14.9% body weight loss with 2.4mg weekly semaglutide over 68 weeks.
- This K-pop video contains zero information about GLP-1 medications like Ozempic or Mounjaro
- Content management systems can incorrectly categorize entertainment as medical information
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- This K-pop video contains zero information about GLP-1 medications like Ozempic or Mounjaro
- Content management systems can incorrectly categorize entertainment as medical information
- Actual GLP-1 content typically discusses dosing, side effects, or weight loss experiences
- The STEP 1 trial showed 14.9% weight loss with 2.4mg weekly semaglutide over 68 weeks
- Always verify that health-tagged content actually contains health information
- Misclassified content can make it harder to find legitimate medical resources
- K-pop fan videos and pharmaceutical discussions are completely different content categories
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
nadi ♡ · TikTok creator
196.1K views on this video
💔 💔💔💔 #kissoflife #kiof #kpop #fyp #kpopfyp
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by nadi ♡, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.